Plain-English translation of NCT06233526 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a new way to treat children whose acute myeloid leukemia (AML) has returned or stopped responding to standard chemotherapy. Instead of using a one-size-fits-all approach, doctors will study the genetic makeup of each child's cancer and test which chemotherapy drugs work best against it in the laboratory. Then they'll create a custom treatment plan based on those results.
Many children with relapsed or refractory AML don't respond well to standard retreatment plans, and there's no agreed-upon best way to treat them. This new treatment aims to give each child the best chance by matching them with chemotherapy drugs that are most likely to work against their specific cancer.
Your child's leukemia cells will be tested in two ways: doctors will analyze the genetic profile of the cancer and test which chemotherapy drugs kill the cancer cells most effectively in the laboratory. Based on these results, a personalized chemotherapy treatment plan will be created for your child. Your child will then receive this tailored chemotherapy, typically followed by a stem cell transplant as part of standard care. You'll have regular clinic visits for treatment, monitoring, and blood work throughout the process.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China